Abstract 274P
Background
Index tumors are recognized as the most aggressive prostate tumors; however, their clinical implications remain unclear. This study aimed to investigate the occurrence of index tumor localization based on zonal origin and explore the impact of these locations on the prognosis after radical prostatectomy among patients with negative surgical margins.
Methods
In this retrospective, single-center study, a cohort of 1,109 consecutive patients who underwent radical prostatectomy was analyzed. The index tumor was defined as the largest tumor within the prostate gland. Localization was determined using McNeal's zonal origin classification on whole-mount sections. Kaplan-Meier survival curves were employed to assess biochemical recurrence (BCR)-free survival. Univariate and multivariate Cox proportional hazards analyses were conducted to identify predictive factors for early BCR (within 1 year).
Results
Among the 621 patients with negative surgical margins and no adjuvant therapy, index tumors were localized in the transitional zone in 191 patients (30.8%), the peripheral zone in 399 patients (64.3%), and the central zone in 31 patients (5.0%). A total of 22 patients (3.5%) experienced early BCR, and 70 patients (11.2%) experienced overall BCR during a median follow-up period of 61.7 months. Based on index tumor location, the early BCR-free rates were 99.5%, 95.7%, and 83.3% for the transitional, peripheral, and central zones, respectively. Multivariate analysis identified the index tumor in the central zone as an independent predictor of early BCR with negative surgical margins following radical prostatectomy, followed by the pathological grade of the prostatectomy specimen, index tumor in the peripheral zone, and a high prostate-specific antigen level.
Conclusions
This study examined the significance of index tumor location among patients with negative surgical margins after radical prostatectomy. Notably, index tumors situated in the central zone, although infrequent, emerged as the most robust predictors of early BCR. These findings may prompt urologists and patients to reconsider their therapeutic strategies for prostate cancer management.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
310P - A study on the prediction of recurrence site of endometrial cancer using various machine learning techniques
Presenter: Wonkyo Shin
Session: Poster Display
Resources:
Abstract
311P - Circulating cytokines in the differential diagnosis of endometrial cancer
Presenter: Tatyana Abakumova
Session: Poster Display
Resources:
Abstract
312P - Molecular and genetic features of squamous cell carcinoma of vulvar cancer depending on HPV status
Presenter: Visola Navruzova
Session: Poster Display
Resources:
Abstract
313P - Efficacy and safety of oral metronomic chemotherapy in recurrent refractory advanced gynaecological cancer: Experience from regional cancer center of eastern India
Presenter: Ranti Ghosh
Session: Poster Display
Resources:
Abstract
314P - Perioperative outcomes in advanced epithelial ovarian cancer treated with neoadjuvant bevacizumab and chemotherapy: Real-world experience from an Indian cancer centre
Presenter: Upasana Palo
Session: Poster Display
Resources:
Abstract
315P - Real-world experience of niraparib as maintenance therapy in newly diagnosed advanced ovarian cancer: A single-center retrospective study
Presenter: Wenxin Liu
Session: Poster Display
Resources:
Abstract
316P - First evidence of olaparib maintenance therapy in patients with newly diagnosed BRCA wild-type ovarian cancer: A real-world multicenter study
Presenter: Jing Li
Session: Poster Display
Resources:
Abstract
317P - Attitudes of Israeli gynecologists towards risk reduction salpingo-oophorectomy at hysterectomy for benign conditions and the use of hormonal therapy
Presenter: wisam Assaf
Session: Poster Display
Resources:
Abstract
319P - Survival prediction for ovarian cancer patients from Taiwan cancer registry data
Presenter: Tzu-Pin Lu
Session: Poster Display
Resources:
Abstract
320P - Treatment patterns and outcomes in Indian patients with advanced ovarian cancer: A single center experience
Presenter: Pushpendra Hirapara
Session: Poster Display
Resources:
Abstract